JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118

Benzinga · 3d ago
JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.